ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP), a $4.4 billion gene editing company whose stock has surged over 21% year-to-date according to InvestingPro data, reported new Phase 1 ...
ZUG, Switzerland and BOSTON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
ZUG, Switzerland and BOSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
-CTX310™ led to durable reductions of angiopoietin-like 3 protein (ANGPTL3) and triglyceride levels in non-human primates (NHPs) after a single dose- CRISPR Therapeutics is advancing a pipeline of in ...
CRISPR gene editing technology is making a name as a genetic swiss army knife. The genetics research community, seemingly limited by only their imagination, have been creating CRISPR applications at a ...
Furthermore, CRISPR Therapeutics plans to release initial Phase 1 data for its cardiovascular assets and longer-term follow-up data for its next-generation CD19 CAR T therapy by mid-2025. Additionally ...
ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, May 14, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that new ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback